SomaLogic Launching Validation and Prospective Trials for Protein Biomarker Lung Cancer Diagnostic

The test is intended both for early screening purposes and the differential diagnoses of lung nodules detected during CT scans and x-rays. SomaLogic has partnered with Quest Diagnostics to commercialize the test, with a lab-developed version slated for launch next year.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.